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Abstract: Major advances in the last few decades have favored the view of inflammatory bowel
disease (IBD) as a disease of hyper- or, more often, paradoxical hyporesponsiveness of the
gut-associated immune system. The relevant pivot seems to be the loss of the balance between
gut-associated pro-inflammatory lymphocytes and the indwelling microbiome species, with inner
regulatory circuits (regulatory T-lymphocytes, T-reg) and outer factors (such as drugs, tobacco, diet
components) contributing to complicate the matter. Light might be shed by the observation of the
real-world IBD epidemiology, which may help unveil the factors that tend to cluster IBD cases to
certain geographical areas. A transitional mind frame between bench and real-world gastroenterology
could hopefully contribute to restrain the mounting epidemic of IBD in the Western world and to halt
the more recent increases seen in many Eastern countries.
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1. Introduction
The (inflammatory) disorders of the alimentary tract have accompanied and conditioned modern
mankind’s history since the 19th century. In this history, inflammation is the keyword, insofar as our
alimentary conduit can transform the simple routine action of feeding into a process of sampling of the
outer world, and then turn the relevant information back to the inner immune system. The disciplines
of medicine, nutrition, behavioral sciences, sociology are all relevant in the study of inflammatory
bowel disease (IBD). We shall henceforth attempt to implement these basic notions with the real-life
positioning of IBD in the human disease spectrum (epidemiology) and test whether this viewpoint can
add to our knowledge of the IBD entity.
2. Overall Background
2.1. Brief History
Ulcerative colitis (UC) was the first IBD to be described. Relevant symptoms were named by
the ancient Greeks [1]; a characterization of the underlying inflammatory process dates back to the
early 1800s [2]. The term “ulcerative colitis” was introduced by Sir Samuel Wilks in 1859 [3]. The first
complete definition of Crohn’s disease (CD) is due to Giovanni Battista Morgagni in 1769 [4], and its
recognition as different from intestinal tuberculosis is classically attributed to Crohn, Ginzburg, and
Oppenheimer (Mount Sinai Hospital, New York 1932) [5]. The separation between colonic CD and UC
was more complex and not very clear until the keystone papers of Lockhart-Mummery and Morson
were published in the sixties [6,7].
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2.2. Essential Macroscopic Structures
Understanding the gut wall structure cannot ignore the three primary gut functions. Immune
surveillance and nutrient absorption rank first and second in the list (and are functionally intertwined,
as reiterated below many times); the aboral movement of luminal contents is the third key function.
These tasks condition the functional existence of two layers: the mucosa and the muscularis propria;
these two layers are then connected by a third layer, the submucosa, with its peculiar blood vessels
and lymphatic collectors [8].
In a functional key of interpretation, which is the declared refrain of this presentation, immune
surveillance is the life-saving function and is exerted in an on-off fashion or alternate pro- and
anti-inflammatory bouts. The steady state of the system may pivot on the tight separation between
the mucosal layer and the overreactive lymphoid tissue underneath. The balance may tip towards
inflammation if the permeability is increased, as a result, for example, of tight-junction damage
inciting a pro-inflammatory bout. In contrast, this response can be contra-regulated by the death
of inflammatory lymphocytes (apoptosis, see below), which may either occur spontaneously or be
drug-induced. As expanded on below, the microbiome is the primary source of inciting antigens in
this scenario [9].
The effector lymphocytes may undergo several cycles of sensitization and replication in the
environment of the Peyer’s patches. These are mucosal lymphoid structures thought to direct both
immunogenesis and tolerance. The keys of these reactions are the M-cells. With their thin, attenuated
membrane, they lie on top of the Peyer’s patch and continuously “sample” the lumen content. Antigens
or microorganisms eventually trespassing the M-cell to reach the patch germinal center may act as
“primers” for the lymphocyte progenies. Such primed cells may ultimately migrate to mesenteric
lymph nodes, then reaching the circulation carrying their message of antigen-specific response [10].
This balance implies that the human alimentary tract makes a continuum with the outer world
at least in the obvious terms of food introduction and processing; this event in turn is governed by
controlled inflammation. The effectors of these events deserve now a closer consideration.
3. Sub-Cellular and Cellular Effectors
3.1. Epithelial Cells
The intestinal epithelium covers the whole inner surface of the gastrointestinal tract, which may
have a surface area of up to 32 m2 in humans [11] and undergoes renewal every 4–5 days in the small
intestine [12].
The intestinal epithelium controls the interactions between microbial flora, environmental factors,
genetic factors, and the host immune response in health and disease (such as IBD). Disruption of the
tight or the adherent junctions can cause intestinal inflammation [13]. Changes of at least two cell
lineages have been linked with the pathogenesis of IBD: (1) goblet cell depletion [14]; (2) homing of a
mutated NOD2 intracellular receptor (an IBD risk factor) to Paneth cell progenies that are defective in
defensin production [15].
3.2. The Defensins
This family of cationic anti-bacterial peptides are released from Paneth cells as alpha-defensins,
and from colonocytes as beta-defensins. One study showed a 50% reduction of expression of
alpha-defensin 5 in patients with CD [16]. Contemporary studies concentrating on functional changes
of OCTN (organic cation transport) (α-defensins are potential substrates of OCTN1 and 2) found
a non-functional mutation hindering the trans-membrane transport of antigenic material in CD,
anticipating the late demonstration of a defective immune competence in this disorder [17]. Emphasis
on mucosal defense mechanisms was reiterated by further studies showing that UC patients may
be poor mucus producers, a finding that matches the demonstration of an increased number of
epithelia-adherent bacteria in these patients [18].
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3.3. Innate Immunity
Innate immunity is largely based on the sensing of lipopolysaccharide (LPS) on bacterial cell
wall, whether speaking of commensals or pathogens. Upon the sensing process, the cytoplasmic
Nuclear Factor-κB (NF-κB) signaling complex is unleashed from its inhibitor and allowed to bind
the promoter regions of pro-inflammatory cytokine genes, including interleukin (IL)-2. Two specific
variants of saccharide sensors are known: the transmembrane Toll-like receptor family (TLR) and
the nucleotide oligomerization domain (NOD) subsets [19–21]. Both subspecies signal through the
adapter molecule My-D88 and recruit the kinases associated with the IL-1 receptor, before sharing the
NF-κB pathway named above [22]. Loss-of-function mutations on chromosome 16 were interestingly
associated with some CD patients in 2001, suggesting an ileal location and a stenosing behavior. Two
points of interest were later associated with the mutations of NOD2. Firstly, such mutations were
found to be absent from Far East cases [23], and interestingly, though, such variants were consistently
found in families affected by the Blau syndrome: children with Blau syndrome typically show arthritis,
dermatitis, and uveitis [24]. The consideration of CD as a disease of immune deficiency was warranted
by these observations.
3.4. Adaptive Immunity
An abnormal adaptive immunity in IBD is suggested by the fact that:
• Some 70% of UC patients are pANCA (perinuclear anti-neutrophil cytoplasmic antibody)
positive [25].
• Most patients with CD present antibodies to Saccharomyces cerevisiae (ASCA), anti-laminaribioside
(ALCA), anti-chitobioside (ACCA), anti-mannobioside (AMCA), anti-laminarin (anti-L), and
anti-chitin (anti-C) antibodies, in addition to other antibodies that target microbial antigens, such
as anti-outer membrane porin C (anti-OmpC), anti-Cbir1 flagellin, and anti-12 antibody. Also,
autoantibodies targeting the exocrine pancreas (PAB) were shown to be highly specific for CD [26].
• Commensal antigens may be erroneously recognized and presented as foreign to pro-inflammatory
Th1 cells (wrong TLRs or wrong antigen-presenting cells may originate these errors) [27]. The issue
of the antigen-presenting cells will be again dealt with below.
3.5. The Microbiome
This term conventionally indicates a 1014 microorganism population mainly dwelling within the
colon [28]. It is now clear that the quantity and quality of the microbiome species reflect states of health
or disease. The microbiome responds to variables that include location, age, drug use, and general
lifestyle. The attention of the investigators has recently been attracted by the ability of the microbiome
to respond and profoundly change in parallel to socio-economic changes in peace (e.g., feeding habits)
or war (e.g., migrations, poverty). Brisk environmental changes may overcome microbiome adaptation
rates, possibly igniting the remodeling of gut inflammation (see the conclusive paragraph). The recent
phenomenon of massive urbanization in many parts of the world has been associated with observed
changes in the microbiota.
4. Predominant Immune Response Bias in the Gut
The gut immune system is primarily biased to tolerance. The processes that effect this tolerance
environment involve many cells and their mediators.
(a) Most of the gut antibody responses are mediated by immunoglobulin (Ig) subclasses that,
incapable to fix complement, can lead to aborted responses [29].
(b) Cell products like mucus and defensins (see above text) can passively avoid close contact between
immunogenic luminal contents and the underneath reactive tissues [18–20].
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(c) The lining epithelium itself constitutes a barrier. Its tight junctions are modulated by zonulin, a 47
KDa protein. Increased zonulin activity can enhance antigens delivery through the paracellular
pathway of intestinal epithelial cells, leading to the abrogation of immune tolerance [30].
(d) Many gut processes are terminated via the specific chain of apoptosis, as opposed to regular cell
death. For a review of the basic effects involved in apoptosis, see reference [31]. Apoptosis is
designed to effect target cell demise while maximally sparing inflammation, a mission that is
pursued by targeting single cell groups to reduce to a minimum the release of chemoattractant
cell debris. Briefly: (a) The intracellular apoptotic death receptors usually recognize members of
the tumor necrosis factor (TNF) family as initiator signals; (b) The execution process is triggered
by the caspase cascade, leading to chromatin and organelle disruption; (c) The mitochondria are
the final common target: irreversible damage to membranes and permeabilization cause oozing
of oxidative compounds promoting cell death.
d.1 Clinical relevance of apoptosis in the setting of IBD Briefly, we wish to reiterate that as
many as three of the routinely used drug classes in the control of IBD can be considered
apoptosis activators.
d.1.1. Sulfasalazine [32] (but not 5-ASA);
d.1.2. Thiopurines and their metabolites 6-thioguanines can abolish the efficacy of
anti-apoptotic factors in lymphocytes via RAC-1 blocking [33];
d.1.3. The anti-TNF monoclonals are caspase inducers and potentially may trigger cell
lysis via complement fixation and initiation of antibody-dependent cell-cytotoxicity
(ADCC) [34].
(e) The Regulatory T-Lymphocytes (T-Regs)
Since their discovery a few years ago, the lymphocyte population CD4+ CD25+ Foxp3+ has
been the target of intense interest. The main reason for this interest rests with the finding that upon
specific antigen (Ag) activation, they can exert specific suppressive effects towards the response
to the relevant Ag. They could become target of future medical therapy [35]. The finding of the
development of autoimmune disorders if T-regs are suppressed and the study of the IPEX syndrome [36]
(polyendocrinopathy-enteropathy-X linked) in congenital T-reg malfunction cooperated in boosting
trust in the T-regs.
5. The Trigger Factors of IBD: Genetic Factors, Drug Factors, Leisure Habits, Diet
5.1. Genetics (1)—The Case for Monogenic IBDs
A monogenic IBD may derive from the loss of function of a gene coding for a non-redundant
process. The result of the latter events is often an IBD-like pathology that is indistinguishable from
genuine IBD [37] but, insofar as aroused by anomaly of a non-redundant yet vital cell function, may
prove life-threatening in early childhood. [38]. We have recently [39] compiled a review of these
conditions; here, we limit ourselves to an arbitrarily selected presentation.
5.1.1. X-Linked Apoptosis Inhibitor
Apoptosis is a crucial cell homeostasis regulator, under the opposing influences of pro- and
anti-apoptotic signaling molecules [40]. Overexpression of anti-apoptotic signaling may be at the
basis of both some cancers and severe inflammatory disorders. All anti-apoptotic molecules share the
ability to bind caspases through baculovirus IAP repeat domains (BIR) [41]. The family of the X-linked
inhibitors of apoptosis protein (XIAP) is the most potent and best studied: it effectively neutralizes
caspases 3, 7, and 9. XIAP invariably leads to a key triad of clinically severe manifestations: sensitivity
to Epstein–Barr virus-induced histiocytosis, recurrent splenomegaly, and IBD [42]. Two pediatric cases
of XIAP malfunction have recently been published. Genetic analysis of the first one [43] revealed a
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G to A substitution at a highly conserved position causing a cysteine to tyrosine switch on the XIAP
molecule; this child underwent eventual progenitor cell transplant with immediate response. The other
case [44] did not undergo bone marrow cell replacement, ran a rocky course, and is now dealing with
unchecked fistulizing CD.
5.1.2. Signal Transduction and Activation of Transcription (STATs)
STATs are a family of mediators of cell signaling during immune responses, with their intact action
depending on the protein family JAK, which can activate specific STATs to downstream signaling [45].
Studies in animal models [46] have shown that loss of STAT function: (a) favors chronic enterocolitis; (b)
increases sensitivity to apoptosis, impairs wound healing, increases sensitivity to endotoxin. An intact
STAT signaling through IL-10R is necessary to prevent such changes. The consanguineous members of
two unrelated families have recently been diagnosed with incurable skin and respiratory infections:
documentation of a loss-of-function mutation of IL-10R disclosed the cause of the life-threatening
disorder and indicated successful bone marrow replacement [47].
5.1.3. A Disintegrin and Metalloprotease (ADAM) 17
ADAM 17 is a disintegrin metalloprotease capable of cleaving TNF, L-selectin, and epidermal
growth factor receptor ligands from plasma membranes. When upregulated, ADAM-17 can control
cancer and inflammation [48]. The multiplex dysfunctions of three children born to consanguineous
parents have recently been described and attributed to failure to activate STAT3 via a normally shed
EGF-R (consequence of lacking ADAM-17). The multiple skin, hair, and gut lesions of these subjects
responded to treatment and were compatible with a nearly normal life [49]. Incidentally, these findings
discourage a strategy of abolishing ADAM-17 to treat inflammatory disease suspected to be due to
excess TNF release.
The reader is referred to our review for an exhaustive coverage of this topic [50].
5.2. Genetics (2)—The IL-23/Th17 Axis as a Significant Pathogenetic Element
The “IL-23/Th17 axis” is now seen as crucial for the development of IBD [51]. IL-23 is a
heterodimeric protein comprising a p19 and a p40 subunit. It is produced by activated macrophages
and dendritic cells stimulated by pathogen ligands or pro-inflammatory cytokines, with negative
feedback mainly provided by downregulatory cytokines including IL-10.
The lymphocytic IL-23 receptor (R) complex consists of IL-23R and IL12 beta1 that classically
contain an extracellular domain, a single transmembrane domain, and a cytoplasmic domain. IL-23
engagement of this IL-23R complex activates at least two members of the JAK–STAT signaling
pathway, i.e., JAK-2 and STAT3. The critical function of this IL-23 pathway is mediation of
inflammation. This is well illustrated by animal models such as IL23p19 transgenic mice that develop an
inflammatory syndrome with lymphocytic accumulations in the small and large intestine accompanied
by extra-intestinal infiltrations as well.
The IL23 system is critical for the differentiation and expansion of Th17 cells that produce the IL-17
cytokine which, in turn, by stimulation of the production of inflammatory mediators—IL-1, IL-6, IL-8,
TNF, and others—endows Th17 cells with their characteristic functions: microbial defense (which is
critical in the polymicrobic colonic environment) and maintenance of chronic inflammation in various
non-autoimmune (infectious) or autoimmune conditions. IL-23 is constitutively expressed in the
terminal ileum but is induced during inflammation, according to animal models, such as cell transfer
and IL-10 knockout mice (reviewed in reference [51]). Of note, myeloid-based STAT3 deficiencies
also lead to the development of colitis, anticipated by the knowledge that functions of STAT3 include
pro-inflammatory activities and regulatory activities mainly dependent on IL-10.
Another downregulatory cytokine that is potently induced by IL-23 is IL-22, which not only
downregulates the degree of IL-23-dependent intestinal inflammation but also promotes epithelial cell
restitution at different sites, i.e., intestine and lungs. Thus, the IL-23/Th17 axis both promotes primary
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inflammatory reactions and drive secondary features of contra-suppression and tissue repair, mostly
via STAT3 activation.
Genome-wide association (GWA) studies have now identified multiple single nucleotide
polymorphisms (SNPs) in the IL-23R gene region as being associated with both CD and UC, with
disease-protective and disease-enhancing polymorphisms of IL-23 identified; the data so far point
to a role of the IL-23/Th17 axis common to the pathogenesis of the two polar IBD phenotypes, UC
and CD. Interestingly, similar SNPs have been identified in inflammatory systemic disorders already
described in association with IBD, i.e., psoriasis and ankylosing spondylitis, emphasizing that the
basic immunologic circuitry that contributes to IBD is likewise operative “beyond the boundaries of
the bowel”.
On the other hand, such complex axes are not thoroughly understood. In animal models, IL-17A
was shown to be protective against T cell-mediated colitis: IL-17A-deficient mice showed rapid weight
loss and severe colitis. It has been postulated that loss of IL-17A could lead to an imbalance of pro-Th1
inflammatory cytokines, leading to severe colitis. In addition, genetically defective IL-17 immunity in
humans was associated with a risk of chronic mucocutaneous candidiasis. Current evidence suggests
that inhibition of IL-17 may induce inflammation in the gastrointestinal tract by favoring Th1 pathways
and/or changing the mycrobiome composition [52].
Being IBD, spondyloarthritis, and psoriasis tightly associated, probably they are not distinct
diseases, but different expression of a common inflammatory process [53].
5.3. Diet
The recent increase of the global prevalence of IBD cannot be simply attributed to genetics: while
only the monogenic forms can readily be explained on this ground, the bulk of the sporadic IBDs call
other factors into question. Among the environmental factors, diet arouses much interest. High intake
of fruits and vegetables seems to reduce the likelihood of manifesting IBD; by contrast, refined cereals,
alcohol, salt, certain oils, fructose derived from corn, fatty meat, and processed foods in Western
regions, all seem to promote inflammatory processes [54]. Both lay magazines and the scientific
literature have synergized in the past years to indicate the so-called “Western diet” as the culprit for
the sufferings of modern society. According to a loose definition, “Western diet” is a feeding style that
is rich in saturated fats, red meat, and carbohydrates and low in fresh fruits, vegetables, whole grains.
In the majority’s opinion, none of the individual components of a Western diet can be blamed for
being pathogenic; rather, the prolonged use of such a feeding style seems to favor loss of microbiome
diversity and propensity to autoimmune disease, including CD. By contrast, people on an agrarian
diet including raw plant and fiber-based foods were less prone to clinical dysimmunity [55].
While the contribution of the diet to the onset of IBD is generally recognized, the influence of
food on the course of the disease is not clear [56]. Special nutritional schemes worked out by pediatric
gastroenterologists play a role in inducing remission in children [57]. Because malnutrition is frequent,
its assessment and nutritional supportive care are important aspects of multidisciplinary patient
management [58]. Apart from yogurt, patients with IBD tend to avoid dairy products fearing an
exacerbation of their symptoms. Nevertheless, there is no convincing evidence that milk and its
derivatives act as triggers for disease recurrence [59].
Diet Could Have Effects Beyond the Bowel
At a close scrutiny, the simple act of feeding implies a dialogue between an extraneous antigenic
load and the lymphoid gut structures, with inflammation playing the arbiter of any imbalance. Indeed,
excess feeding, overweight, and serum inflammatory markers are easily found in American lower-class
children [60]; further intriguing and worrisome, is the consistent finding of an intellectual decline in
these premises [61], as we describe below.
Dror et al. [62] published a study regarding the possible link between incorrect diet and intellectual
decline. If the complex of these changes was known to accompany obviously pathologic alimentation,
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the team of Dror has recently described the changes attached to routine feeding [62]. Their research
was based on two basic demonstrations. Firstly, pancreatic B cells producing insulin abundantly
display receptors for IL-1β (the chief pro-inflammatory cytokine): insulin secretion may be an
immune-inflammatory event. Secondly, routine feeding from the immunologic point of view is
a barely tolerated process, with a peritoneal macrophage reaction being raised in response to bacterial
products (LPS) leaking from the intestinal wall. Thus, in this scenario, activation of Langerhans cells
and insulin release upon feeding are promoted by the two events of blood glucose elevation and IL-1
beta release from primed macrophages; the crucial side effect is the upgrading of inflammation in
the system [63]. Notably, in this chain of events, glucose can preferentially be captured by activated
immune cells displaying the GLUT-1 receptor (this receptor class allows glucose uptake in the absence
of insulin). The competition for glucose between immune cells and neural tissues might have caused
human brain shrinking in archaic eras; nowadays, it may be the explanation for the intellectual decline
described in some epidemiologic studies [64].
These findings might underscore the gut inflammogenic potential.
5.4. Induction by Drugs
Drug-induced IBD can be triggered or exacerbated by non-steroidal anti-inflammatory or other
drugs that interfere with anti-inflammatory prostaglandins [65]. However, the study of drug-induced
IBD has recently focused on anti-TNF agents. Most interestingly, a review of the unwanted effects
of the formulations used in the last decade for a variety of immune-mediated diseases, including,
particularly, rheumatoid arthritis (RA) and IBD itself, has revealed that such drugs can unpredictably
induce a paradoxical IBD, together with cases of psoriasis and uveitis [66].
Etanercept is a fusion protein that blocks the TNF receptor without inducing lymphocyte apoptosis
and is the drug most frequently implicated in this immunologic toxicity [66]. Its ineffectiveness
in the treatment of IBD, but not in rheumatoid disorders compared to other anti-TNF drugs like
infliximab and adalimumab, is probably due to distinct disease processes and different mechanisms of
action of the drugs. Both infliximab and etanercept neutralize TNF-alpha, but infliximab complexes
are more stable with membrane-bound TNF than etanercept. However, only infliximab can bind
to peripheral blood lymphocytes and lamina propria T cells and induce apoptosis of activated
lymphocytes. Infliximab can lyse TNF-producing cells by complement activation, but etanercept
cannot. The use of etanercept in ankylosing spondylitis patients is associated with an increase in
interferon-γ-positive and TNF-α-positive CD4+ T cells and CD8+ T cells. An increase in the production
of these cytokines in genetically predisposed patients may induce IBD [67].
A recent study has shown that TNF inhibitors can increase the expression of the α-4/β-7 integrin
in CD4+ lymphocytes, so boosting the gut-seeking potential of the pro-inflammatory cells that happen
to be present in these populations [68]: thus, such findings can provide a clue to the understanding
of the paradoxical autoimmune effects of TNF-α blockers. In clinical practice, we encountered a
22-year-old male who, treated with etanercept for juvenile RA, developed histologically evident UC
unresponsive to azathioprine and also to adalimumab and infliximab [69]; this patient is currently
been considered for bone marrow transplant. Again, these data suggest that common mechanisms
underlie the pathogenesis of numerous immune dysfunction phenotypes including IBD.
5.5. Leisure Habits: Smoking
The effects of tobacco on IBD have long eluded investigators’ efforts: patients with CD who
continue to smoke were classically known to worsen or need more drugs to maintain remission,
whereas those with UC had long learnt that “lighting up” would prove protective, with frequent
drug sparing. Even more intriguing and clinically meaningful, patients with UC (but not those with
CD) who smoke are known to often experience a severe disease flare, occurring months or even
years after quitting cigarettes [70]. A satisfactory answer to this confusing evidence came from the
results of experiments wherein animals underwent an LPS-driven septic shock [71]. Briefly, it was
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shown that the expansion of this response could be controlled by a resected vagal fiber; furthermore,
the mediator of this vagal protective action was acetylcholine (Ach). Specifically, Ach was found to
bind the macrophagic nicotinic receptor α-7-nAchR, blunting the subsequent release of inflammatory
cytokines [72]. At this point, it is easy to envisage that tobacco can restrain UC through the binding of
the same nicotinic receptor, and, similarly, that disease rebound can be expected following tobacco
quitting and clearance from Ach of the binding site on inflammatory macrophages. Experiments of
vagal nerve stimulation to treat various phases of IBD are currently under way [73].
6. The Kick-Out Factors in IBD: Antigen-Presenting (Dendritic) Cells
Proper antigen presentation to pro-inflammatory lymphocytes by dendritic cells is vital for an
efficient yet regulated reaction: an excessively short half-life of the antigen-presenting cells (APCs)
would leave lymphocytes short of the inciting antigen, but an excessive APCs persistence can obviously
lead to detrimental inflammation [74]. This might happen in some IBD cases, wherein failure of APCs
to die out (apoptosis resistance) may not only cause uncontrolled immunity but also cause failure to
recruit T-reg cells (see also the above text), insofar as T-regs depend on a correct function of APCs [75].
APCs may commonly become resistant in protracted IBD inflammation, if they become replaced by
the so-called non-professional APCs [76].
7. IBDs in Real Life: Clues from Epidemiology
The preceding paragraphs, containing a robust deal of basic science, have confirmed a core
of rather classic concepts on IBDs, as follows. IBDs are multifactorial syndromes pivoting on
the phenomenon of inflammation. Though presenting as a response to the outer environment,
inflammation is also sustained by inner immunologic variants, which, beyond other features, impart to
IBD the behavior of a low-penetrance genetic defect. Analysis of the way specific disease cases cluster
together can shed light on their etiology and pathogenesis; on the basis of this tenet, we decided to
conclude this tentative review with an emphasis on the epidemiology of IBD.
7.1. World Epidemiology
It is estimated that currently >3 million individuals have IBD in Europe, and the global population
includes 5 million of patients with IBD. A time-trend analysis has shown that 75% of CD studies and
60% of UC studies reported an increasing incidence of statistical significance [77].
7.2. East Meets West: A Paradigm for the Role of Environmental Factors
Rapid industrialization and inurbation of wide areas in the East (see below) has coincided with
increasing incidence and prevalence of IBD. Recent studies have reported an IBD incidence over Asia
of 1.37 per 100,000, with figures of 3.4 per 100,000 for China. These figures indicate a trend to rise,
if compared with traditional incidence figures of 0.60–3.44 [78]. As early as 2015, the reasons for
this escalation were enumerated as: life westernization, use of appendectomy, milk formula feeding,
changing diets (to be covered below) [79]. These data are confirmed by a rising incidence of IBD of
epidemic proportions in some Iran regions featuring aggressive industrialization [80].
7.3. Similar Orders of Figures Have Long Been the Matter of Scrutiny with Regard to the Incidence of Pediatric
IBD (CD) in the South Island of New Zealand
Data from a recent study [81] have confirmed an epidemic-like behavior of CD in the area, with
one of the highest incidence peaks worldwide. Causative hypotheses, including reduced bioavailability
of vitamin D in the area, are fueling an instructive debate.
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7.4. Clues from Migratory Events
Relevant information can be obtained from migration studies. In Canada, Eastern families which
adopt a Western lifestyle may achieve IBD incidence figures that match those of the other inhabitants;
children seem to be maximally sensitive to local injuring factors (detailed below) [82]. Cuban exiles
rejoining their families in Florida have been described to achieve a “North American” IBD risk.
Interestingly, though, the authors of the survey have observed a progressive decrease of the lag time
between arrival to Florida and IBD onset [83]. Responding to the authors’ queries, we set forth the
hypothesis of a worsening anxiety of the migrants in response to the rapid changes of the social
conditions in the USA in the last year, fueling further inquiries [84]. Thus, studies of the IBD dynamics
have raised more questions than answers, and it is with genuine anticipation that we reappraised a
few recent studies of urbanization of IBD patients emphasizing the role of the microbiome changes.
8. Urbanization: IBD Epidemiology and Microbiome
Urbanization makes global changes in these days, and, on a simple frequency basis, cannot
avoid affecting a proportion of IBD cases. The crucial observation is that city limits make a kind of
a “secluded” environment, where factors are identifiable and, hopefully, easier to classify. On the
basis of these premises, a researcher from Lund (Sweden) asked how the urban environment changes
organism ecology. Of utmost relevance and luck for our topic, the author chose two measures
that characterize IBD: oxidative stress and inflammation [85]. To this end, we like to incidentally
emphasize that the recognition of “pro-inflammatory factors” in urbanized areas has already been
made by non-gastroenterologists, who have proposed for those exposed to such factors the fantasy
label “inflammacitizens” [86]. Noise pollution of city areas may be chronic (public and private
transportation) or occasionally acute (concerts, festivals, etc.). Noise can obviously favor anxiety.
Relevant to the issue of IBD, we have above stressed a possible link between increased anxiety levels
and increasingly aggressive IBD in Cuban exiles migrating to the US [83]. Exuberant light at night is a
matter of boast for many Western cities. Unfortunately, experts in feeding behavior and gut diseases
may see prolonged night illumination as a chance for unduly prolonged access to food (often street
junk food), hence a pro-inflammatory factor [87].
Hereunder, we briefly comment on three of the urban factors that this Swedish investigator has
linked to disturbed inflammation and oxidative stress.
8.1. Chemical Pollution
Heavy metals, nitrogen oxides, nanoparticles (the well-known PM10 from vehicles’ exhaust pipes),
and polycyclic hydrocarbons are all pro-inflammatory and can increase reactive oxygen species (ROS)
formation [85,88].
8.2. Infectious Disease
Unexpectedly, research has shown that city life may be a risk for infectious diseases. The agent
might often be a wild animal, which will be variously attracted by the presence of water pools or, most
importantly, by the availability of food leftovers by restaurant backdoors [89]. Birds and foxes might
be the frequent vehicles, with lower class children most frequently affected. In the US, it is reckoned
that most children from low-income families might experience up to five diarrheal episodes before the
age of 5 years, a condition that predisposes to chronic mesenteric inflammation favoring CD [90].
8.3. Lack of Physical Exercise and Microbiome
Nowadays, it is being emphasized that a diet poor in vegetables makes a poor antidote against
inflammation. The presence of processed meat and deep-fried cooking used by many city workers
coping with nightshifts can favor the intestinal growth of the Bilephila wadsworthi, a pathogen capable to
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erode intestinal defensins and expose the mucosa to the pro-inflammatory action of further pathogens.
We have covered this issue in a recent review [91].
The availability of efficient means of transportation and strict schedules obviously force most
citizens to use subways and connecting train services, preventing people from walking. Unfortunately,
physical exercise is one efficient means to activate muscles to release their myokines (IL-6, IL-8,
IL-15) which in turn will direct the monocytic release of lactoferrin. [92]. To this end, we emphasize
that lactoferrin exerts its potent anti-inflammatory effect ever since the newborn phase, where it is
secreted in colostrum, through the adult phase, where it contributes to the selection of intestinal
Bifidobacteria [93] and terminates inflammation by disrupting the inciting LPS molecules [93]. In other
words, muscles are the forgotten immunoregulatory organs involved in the lactoferrin circuitry, and
evidence is already sufficient to state that people neglecting physical activity are strong candidates to
(dys)immune disease.
At this point, a description of the microbiome changes underlying the facts described above is
largely due. A recent review of microbiota and urbanization [94], mastered by a group based in China
and Australia, turns out to be of an utmost usefulness. Taking advantage of the peculiar position
of their observatory at the opposite side of Europe, the authors are familiar with data from several
regions that have recently hosted brisk society changes (including urbanization), with China and
its huge population contributing a significant example. The reports from the Asia-Pacific Crohn’s
Colitis Epidemiology study (ACCESS) compared the incidence of IBD in Australia with that in China,
Hong-Kong, Sri Lanka, Indonesia, and other countries: it was found that the highest figures coincided
with the most industrialized and inurbated regions [95]. In a meta-analysis of 40 studies [96], the
authors examined the pooled incidence ratios of IBD between urbanized and rural regions, finding a
significantly higher IBD risk for the urbanized areas. As expected, these data strongly suggested a link
between IBD risk and urbanization.
Should one then ask about the microbiome configurations underlying these IBD risk maps, a few
tenets might be the key to interpretation: (1) The microbiome composition is highly flexible and adapts
to the subject’s prevalent alimentation; (2) Thus, microbiome configuration, by and large, might mirror
ways of feeding; (3) Loss of given microbiome species because of a supervening lack of substrate can
be replaced by exchange of body fluids (chiefly saliva) with other subjects. Paradoxically, in these
cases, increased promiscuity should be regarded as a positive value (reviewed in reference [94]).
In general, populations living on agricultural products are rich in the Prevotella and Xylanibacter
genera that have the machinery for cellulose and xylan hydrolysis; their urbanized counterparts, by
contrast, are rich in Bacteroides, Alistipes, Blautia, Ruminococcus, and Bilophila [97].
Several studies have shown that there is a significant reduction in the diversity of the stool
microbiome of individuals with IBD: 25% fewer genes were detected in the fecal samples of IBD
patients than in those of control patients. Dysbiosis is associated with the pathogenesis of IBD, but it is
not clear whether this is a cause or a result of the inflammatory process.
The microbiota of patients with IBD is characterized by depletions of bacteria with
anti-inflammatory effects, including Bifidobacterium adolescentis, Faecalibacterium prausnitzii, and other
butyrate-producing bacteria, such as Dialister invisus, and an expansion of pathogenic bacteria
(pathobionts), including Proteobacteria such as adherent-invasive Escherichia coli (AIEC), Ruminococcus
gnavus (a mucolytic bacteria), Campylobacter concisus [98].
The number of sulfate-reducing bacteria, such as Desulfovibrio, is higher in IBD patients, resulting
in the production of hydrogen sulfate that damages intestinal epithelial cells and induces mucosal
inflammation. An increase in ambient oxygen levels induced by hyperemia and increased vascular
and mucosal permeability is thought to be one of the mechanisms responsible for the reduction of
obligate anaerobes (Clostridium groups IV or XIVa), with expansion of aerobes and facultative anaerobes
(Enterobacteriaceae). Figure 1 is intended to highlight a few of the basic concepts enumerated above.
If naturally delivered, a newborn is exposed to the environmental microbiota of maternal origin,
an essential station on the road to a healthy growth. The mode of delivery strongly affects the
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composition of the microbiota. In the case of caesarean delivery (C-section), other environmental
bacteria form the basis for the microbiota, instead of vaginal and fecal bacteria from the mother,
reportedly resulting in a substantial reduction of Bifidobacteria. Other factors influencing microbiota
composition are the type of infant feeding, gestational age, infant hospitalization, and antibiotic use
by the infant. The microbiota of breast-fed infants is dominated by Bifidobacteria, whereas the counts
of E. coli, Clostridium difficile, Bacteroides fragilis, and Lactobacilli are higher in exclusively formula-fed
infants. The first microbes colonizing the intestinal tract hold a pivotal role. Once the core microbiota
has developed, it stabilizes to become less sensitive to modification. Life events such as diet changes,
illnesses, and antibiotic treatments disturbing this settlement process were associated with large shifts
in the abundances of major groups in the affected infants [99].
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Figure 1. Dysbiosis is an unfavorable composition and function of the gut microbiota. Host–microbiota
interactions and host immune syste are both disturbed by dysbiosis. The latter, rather than the
presence of specific pathogens, is likely to affect the development of inflammatory bowel diseases.
Relevant changes may include reduction of anti-inflammatory Phila (Bifidobacteria) and expansion of
pathogenic Proteobacteria (Ruminococcus and Desulfovibrio). Barrier integrity and innate and adaptive
immunity can all be affected by the changes. Hyperactivation of Th1 and Th17 cells, increase of
tight junction permeability, reduction of T-regs, and decrease in REG3gamma and IL-10 are the cell
counterpart of these disorders.
Metageno ic seque ci f I ti ts r l ll r s f icr io e dysbiosis with a
general reduction in the diversit of t e icro ial co it co pared to healthy controls (HC).
Metagenomics has expanded the ability not only to detect icrobial co unities but also to provide
insight into the functional effects of the icrobial co position in IB . In particular, etagenomics
allows the investigation of the distribution of virulence factors across the microbiome, which has
not been systematically studied or previously reported in IBD. A greater prevalence of virulence
factors from E. coli in IBD patients has been observed. Virulence factors from Clostridium perfringens
were only present in patients with IBD and undetectable in HC. The most prevalent virulence factors
that were identified among the IBD cohort are Enterotoxin (senB) (22%), Hemoglobin protease (vat)
(17%), Hemolysin A (hlyA) (11%), Hemolysin B (hlyB) (10%), Hemolysin C (hlyC) (10%), Hemolysin D
(hlyD) (10%), Cytotoxic necrotizing factor 1 (cnf1) (10%), invasion protein IbeA (ibeA) (9%), Secreted
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autotransporter toxin (sat) (8%), and Tir domain-containing protein TcpC (tcpC) (8%). Thus, the
expression of virulence factors in a dysbiotic microbiome may contribute to pathogenesis in IBD [100]
Geographical differences are very important, and the selection of controls in the studies is crucial
to correctly interpret the results. It is well known that host lifestyle affects gut microbiota; the gut
microbiota harbored, for example, by the Chinese population is different from that harbored by the
Western population. Despite the overall microbial difference, the results of the differential abundance
analyses in a recent study [101] suggest that the microbial shift in Chinese IBD patients, compared to
HC subjects, may resemble that in Westerners. These findings suggest that there are consistent changes
in the gut microbiota of IBD patients across populations and that these changes can serve as universal
biomarkers for the classification of IBD states.
The gastrointestinal microbiota can be divided into two ecosystems: the luminal microbiota in
the feces and the mucosal microbiota that is present in the intestinal epithelium. Because of its close
proximity, the mucosal microbiota is more likely to be involved in intestinal diseases than its luminal
counterpart. Mucus layers, composed of a dense inner mucus part and a loose outer mucus fraction,
play an important role in protecting intestinal epithelial cells from the gut microbes and pathogenic
microorganisms. Most of the gut microbiota is present in the outer mucus layer. Inflammatory
responses lead to a reduction in the number of goblet cells and reduce mucus layer thickness, altering
mucus composition. These changes enable easy contact of microbes with epithelial cells, stimulating
an inflammatory response. However, owing to the ease of acquisition and ethical considerations, most
previous studies examined the fecal microbiota rather than the mucosal-associated counterpart.
These pathologic trends are thought to further worsen in more “educated” societies where
sophisticated human relationship or simple prejudice have inadvertently sowed erroneous behaviors.
For example: the widespread use (now decreasing) of the cesarean section at birth [102] has deprived
millions of children all over the world of the gift to “sign” their microbiome with their mothers’ vaginal
flora; excessive hygiene has prevented an early education of their immune system; inhibition of free
contact with their playmates has hampered the reconstitution of microbiome diversity [103].
Recommendations such as that of encouraging promiscuity and unleash children to play in the dirt
may sound absurd to those struggling for the approval of rules that restrain Helicobacter pylori infection
(just as an example) but may be welcomed as a rediscovered wisdom by all those who are worried
by the yet glittering landscapes of Western cities being invaded by crowds of “inflammacitizens” [86]
depressed and debilitated by immune diseases [104].
9. An Attempt at a Holistic Vision
The factors previously mentioned as associated with IBD, i.e., the environment, the genes, the
microbiota, and the immune system, may all be critically important but, given their individual
complexity, they may call for a functionally integrated vision. The concept of an interactome does
underlie this endeavor. In its broadest definition, an interactome indicates the whole set of molecular
interactions in a given cell. Such interactions may regard antigens (for example proteins) but can also
describe sets of indirect interactions among genes [105]. Of course, this brief paragraph is not meant
at all to enter the complex matter of interactomes in any depth. For the sake of our IBD topic, we
wish to succinctly remark that an interactome may also be intended to identify sets of mechanisms
that are indispensable for a disease to be maintained, and, ideally, families of drug molecules capable
to target those mechanisms to effect disease termination. Intuitively, such attempts may acquire
specific importance in the case of chronic inflammatory disorders, (i.e., IBD), wherein the availability
of precisely aimed bullet drugs is eagerly awaited in the face of the unacceptable toxicity often linked
to inaccurate target framing as per conventional algorithms.
The construction of the interactome can start with a seed gene selection derived from existing
databases, such as genome-wide associated studies; synergy with current literature will be followed
by algorithms designed to identify a particular molecular neighborhood of the network that represents
the “disease module”; this will then be validated on the basis of gene expression data, gene ontologies,
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other pathways, etc. Such a process should allow to reach a biological interpretation of the disease
module, the prioritization of the most important pathway(s), and the identification of the molecular
targets that control the whole disease network (the disease interactome). Next, high-throughput
discovery screening should match drugs existing in compound databases with the molecular targets
identified in the disease interactome [106]. To define the IBD interactome, new concepts and tools
are needed to implement the approach: an unbiased data-driven integration strategy that reveals key
players of the system, pinpoints the central drivers of inflammation, and enables the development
of targeted therapies. Powerful bioinformatics tools able to query and integrate multiple “omes” are
available, enabling the integration of genomic, epigenomic, transcriptomic, proteomic, metabolomic,
and microbiome information to build a comprehensive molecular map of IBD. As anticipated above,
this approach will enable the identification of IBD molecular subtypes, correlations with clinical
phenotypes, and elucidation of the central hubs of the IBD interactome that will aid the discovery of
compounds that can specifically target the hubs that control the disease [107].
In our (perhaps biased) opinion, inflammation makes one of these IBD hubs: its place in evolution,
its functions, and the mode these functions are exerted support this view: (1) Inflammation is one
of the most conserved biological processes [91]; (2) Besides its occasional roles of acute defense, it
prevalently acts as a lingering arbiter of the immune dialogues at the barrier gut surface [86]; (3) In its
peculiar variant classified as “apoptosis”, these functions are paradoxically exerted “in the absence of
inflammation” [31], a key pathway to tissue integrity.
10. Conclusive Thoughts
For years, the inflammatory disorders of the gut have been thought to depend on ill-defined
infections or autoimmunity. The discovery and (partial) characterization of the microbiome has
impacted these uncertainties: it was shown that the microbiome turns the gut into a sort of “sixth
sense” capable to continuously probe the outer world and elicit a remodeling inflammation, which
may be the basis of what we named “IBD”. This knowledge is now opening the path to behavioral
therapeutic approaches, reaching beyond the mechanistic use of traditional immune modulators
or surgery.
As the final message from this review, we like to stress that the knowledge accumulated so
far permits to move from the concept of IBD as an “accident coming out of the blue” towards the
understanding of a “protagonist complex of changes originating from the gut (but not exclusively
affecting the gut) that deepens its roots into the socio-economic variables of contemporary societies”.
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